You have 9 free searches left this month | for more free features.

CD27 expressing Hematologic Malignancies

Showing 1 - 25 of 4,985

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

CD19 Expressing Malignancies, Hematologic Malignancy Trial in United States (PBCAR19B)

Recruiting
  • CD19 Expressing Malignancies
  • Hematologic Malignancy
  • PBCAR19B
  • Gilbert, Arizona
  • +6 more
Nov 8, 2022

Non-hodgkin Lymphoma, Acute Lymphoblastic Leukaemia, Chronic Lymphocytic Leukemia Trial in Tianjin (CC312)

Recruiting
  • Non-hodgkin Lymphoma
  • +2 more
  • CC312
  • Tianjin, Tianjin, China
    InstituteHBDH
Sep 12, 2023

Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, High-risk Myelodysplastic Syndrome Trial (VIP943)

Not yet recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • (no location specified)
Sep 5, 2023

Hematologic Malignancies Trial in Zhengzhou (RD13-02 cell infusion)

Recruiting
  • Hematologic Malignancies
  • RD13-02 cell infusion
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Jun 26, 2023

Blood Cancer Trial (KCAT19 T cells)

Not yet recruiting
  • Blood Cancer
  • KCAT19 T cells
  • (no location specified)
May 20, 2022

Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial in Germany (Cyclophosphamide (Non-IMP,

Not yet recruiting
  • Acute Myeloid Leukemia, in Relapse
  • Acute Myeloid Leukemia Refractory
  • Cyclophosphamide (Non-IMP, Lymphodepletion)
  • +3 more
  • Ulm, Baden-Württemberg, Germany
  • +4 more
Jul 24, 2023

Hematopoietic Stem Cell Transplantation, Hematologic Malignancy Trial (CliniMACS®)

Not yet recruiting
  • Hematopoietic Stem Cell Transplantation
  • Hematologic Malignancy
  • CliniMACS®
  • (no location specified)
Oct 17, 2023

B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL Trial in Louisville (Cyclophosphamide, Fludarabine, ACE1831)

Recruiting
  • B-cell Lymphoma
  • +5 more
  • Louisville, Kentucky
    Norton Cancer Institute
Jan 24, 2023

Hematologic Malignancies Trial in Assiut (CD56)

Recruiting
  • Hematologic Malignancies
  • CD56
  • Assiut, Egypt
  • +1 more
Jul 20, 2022

Adult Relapsed/Refractory B-cell Hematologic Malignancies Trial in Beijing (CD19-CAR-NK)

Recruiting
  • Adult Relapsed/Refractory B-cell Hematologic Malignancies
  • CD19-CAR-NK
  • Beijing, Beijing, China
    The Fifth Medical Center of Chinese People's Liberation Army (PL
Dec 1, 2022

B-Cell Lymphoblastic Leukemia/Lymphoma Trial in Kunming (Anti-CD19 UCAR-NK cells)

Recruiting
  • B-Cell Lymphoblastic Leukemia/Lymphoma
  • Anti-CD19 UCAR-NK cells
  • Kunming, Yunnan, China
    920th Hospital of Joint Logistics Support Force of People's Libe
Dec 19, 2022

Acute Lymphoblastic Leukemia, B-cell Lymphoma, Chronic Lymphocytic Leukemia Trial in Xuzhou (allogenic CD19-CAR-NK cells)

Recruiting
  • Acute Lymphoblastic Leukemia
  • +2 more
  • allogenic CD19-CAR-NK cells
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Feb 11, 2023

B-cell Lymphoma, B-cell Leukemia Trial in Kunming (anti-CD19 UCAR-NK cells)

Withdrawn
  • B-cell Lymphoma
  • B-cell Leukemia
  • anti-CD19 UCAR-NK cells
  • Kunming, Yunnan, China
    Kunming Hope of Health Hospital
Nov 27, 2022

Hematological Malignancies Trial (Anti-CD7 CAR-T)

Not yet recruiting
  • Hematological Malignancies
  • Anti-CD7 CAR-T
  • (no location specified)
Jul 8, 2022

CLL/SLL, NHL, Mantle Cell Lymphoma Trial in United States (SYNCAR-001, STK-009, Cyclophosphamide)

Recruiting
  • CLL/SLL
  • +6 more
  • Duarte, California
  • +4 more
Jan 12, 2023

NHL, Relapsed, Adult, B-cell Lymphoma, B-cell Leukemia Trial (KUR-502)

Not yet recruiting
  • NHL, Relapsed, Adult
  • +3 more
  • KUR-502
  • (no location specified)
Aug 2, 2022

Hematologic Diseases, Hematologic Malignancy, Acute Lymphoblastic Leukemia Trial in Miami (device, procedure, drug)

Withdrawn
  • Hematologic Diseases
  • +5 more
  • CliniMACS
  • +7 more
  • Miami, Florida
    Miami Cancer Institute at Baptist Health, Inc.
Sep 26, 2022

Pediatric Hematologic Malignancies Trial in Saint Louis (Ex Vivo T-cell receptor alpha-beta and CD19+ Depletion using CliniMACs

Not yet recruiting
  • Pediatric Hematologic Malignancies
  • Ex Vivo T-cell receptor alpha-beta and CD19+ Depletion using CliniMACs Plus
  • Saint Louis, Missouri
    Washington University School of Medicine
Jul 20, 2022

Tumors, Hematologic Tumors, Tumors by Site Trial in Wuhan (RD13-02 cell infusion)

Recruiting
  • Neoplasms
  • +3 more
  • RD13-02 cell infusion
  • Wuhan, Hubei, China
    Union Hospital, Huazhong University of Science and Technology
Jun 8, 2023

Acute Myelogenous Leukemia, B-cell Acute Lymphoblastic Leukemia, Blastic Plasmacytoid Dendritic Cell Tumor Trial in United

Completed
  • Acute Myelogenous Leukemia
  • +3 more
  • XmAb14045
  • Jacksonville, Florida
  • +8 more
Mar 4, 2022

Relapsed and/or Refractory Acute Myeloid Leukemia, High Risk Hematologic Malignancies Trial in Langfang (anti-CD33 CAR T cells)

Not yet recruiting
  • Relapsed and/or Refractory Acute Myeloid Leukemia
  • High Risk Hematologic Malignancies
  • anti-CD33 CAR T cells
  • Langfang, Hebei, China
    Hebei Yanda Lu Daopei Hospital
Jun 30, 2022

Relapsed/Refractory, High Risk Hematologic Malignancies, T-ALL/Lymphoma Trial in Langfang (CD7CAR T cells)

Recruiting
  • Relapsed/Refractory, High Risk Hematologic Malignancies
  • T-ALL/Lymphoma
  • CD7CAR T cells
  • Langfang, Hebei, China
    Hebei Yanda Lu Daopei Hospital
Jun 30, 2022

Acute Lymphoid Leukemia, B-Cell Leukemia, Leukemia, Lymphocytic, B Cell Trial run by the National Cancer Institute (NCI)

Not yet recruiting
  • Acute Lymphoid Leukemia
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 17, 2022

Hematologic Malignancies Trial in Hangzhou (RD13-01 cell infusion)

Completed
  • Hematologic Malignancies
  • RD13-01 cell infusion
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital,College of Medicine, Zhejiang Univ
Jan 8, 2022

"Don't Eat me" Signal in Hematological Malignancies: CD24 as New

Recruiting
  • Mantle-cell Lymphoma
  • B Cell Chronic Lymphocytic Leukemia
    • Monza, MB, Italy
      Andrea Aroldi
    May 24, 2023